Tech Company Financing Transactions
Nurix Therapeutics Funding Round
On 3/13/2020, Nurix Therapeutics announced $120 million in funding from Foresite Capital, Bain Capital Life Sciences and Boxer Capital.
Transaction Overview
Company Name
Announced On
3/13/2020
Transaction Type
Venture Equity
Amount
$120,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds from the financing will enable the company to advance Nurix's wholly owned development candidates into clinical development.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
1700 Owens St. 205
San Francisco, CA 94158
USA
San Francisco, CA 94158
USA
Phone
Website
Email Address
Overview
Nurix Therapeutics (Nasdaq: NRIX) is focused on the discovery and development of small molecule inhibitors of ubiquitin ligases to treat a broad range of proliferative and degenerative diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Sands
Vice President
Jean Chang
Vice President
Cristiana Guiducci
VP - Bus. Development
Pierre Beaurang
VP - Finance
Hans Houte
VP - General Counsel
Christine Ring
VP - R & D
Gwenn Hansen
Browse more venture capital transactions:
Prev: 3/13/2020: Exuma Biotech venture capital transaction
Next: 3/13/2020: Validere venture capital transaction
Share this article
News on VC Transactions
We do our best to report on all VC transactions involving tech companies. VC transactions reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs